BACKGROUND: The psychiatric side effects of interferon, often responsible for dose reduction or treatment discontinuation, represent a major limitation in the treatment of chronic hepatitis C (CHC). AIM: To prospectively assess the impact on adherence and sustained virological response (SVR) of the occurrence of psychiatric side effects during peginterferon and ribavirin therapy for CHC. METHODS: Ninety-eight consecutive treatment-naïve CHC patients receiving a standard course of peginterferon plus ribavirin were systematically screened for psychiatric side effects, using DSM-IV, at baseline and both during and after treatment. RESULTS: Psychiatric side effects occurred in 38 patients (39%), mostly within the first 12 weeks (87%), and always consisted of mood disorders. Overall, 68% of patients achieved an SVR (71% of patients with mood disorders and 68% of those without; P = N.S.). Peginterferon and ribavirin dose reductions did not differ between patients with mood disorders and those without (46% vs. 37%, respectively; P = N.S. and 13% vs. 22%, respectively; P = N.S.). Anti-viral therapy had to be discontinued in four patients (nonresponse: two, hyperthyroidism: one, psychiatric event: one). CONCLUSION: Early detection and appropriate management of psychiatric side effects during peginterferon and ribavirin therapy for CHC allow optimizing adherence and virological efficacy.
BACKGROUND: The psychiatric side effects of interferon, often responsible for dose reduction or treatment discontinuation, represent a major limitation in the treatment of chronic hepatitis C (CHC). AIM: To prospectively assess the impact on adherence and sustained virological response (SVR) of the occurrence of psychiatric side effects during peginterferon and ribavirin therapy for CHC. METHODS: Ninety-eight consecutive treatment-naïve CHCpatients receiving a standard course of peginterferon plus ribavirin were systematically screened for psychiatric side effects, using DSM-IV, at baseline and both during and after treatment. RESULTS:Psychiatric side effects occurred in 38 patients (39%), mostly within the first 12 weeks (87%), and always consisted of mood disorders. Overall, 68% of patients achieved an SVR (71% of patients with mood disorders and 68% of those without; P = N.S.). Peginterferon and ribavirin dose reductions did not differ between patients with mood disorders and those without (46% vs. 37%, respectively; P = N.S. and 13% vs. 22%, respectively; P = N.S.). Anti-viral therapy had to be discontinued in four patients (nonresponse: two, hyperthyroidism: one, psychiatric event: one). CONCLUSION: Early detection and appropriate management of psychiatric side effects during peginterferon and ribavirin therapy for CHC allow optimizing adherence and virological efficacy.
Authors: Peter L Franzen; Daniel J Buysse; Mordechai Rabinovitz; Bruce G Pollock; Francis E Lotrich Journal: Psychiatry Res Date: 2010-04-09 Impact factor: 3.222
Authors: Jeffrey J Weiss; Sarah Prieto; Norbert Bräu; Douglas T Dieterich; Sue M Marcus; Alicia Stivala; Jack M Gorman Journal: Int J Psychiatry Med Date: 2018-01-03 Impact factor: 1.210
Authors: Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried Journal: Am J Gastroenterol Date: 2011-07-19 Impact factor: 10.864
Authors: Megan M Marron; Stewart J Anderson; Jessica Garrity; Charles F Reynolds; Francis E Lotrich Journal: Psychosom Med Date: 2015-10 Impact factor: 4.312
Authors: Montserrat Masip; Laura Tuneu; Neus Pagès; Xavier Torras; Adolfo Gallego; Josep Maria Guardiola; María José Faus; Maria Antònia Mangues Journal: Int J Clin Pharm Date: 2015-08-13
Authors: Benjamin J R Stewart; Deborah Turnbull; Antonina A Mikocka-Walus; Hugh A J Harley; Jane M Andrews Journal: J Clin Psychol Med Settings Date: 2013-12